ANDA 76818, held by Watson Labs Inc. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 76818 (Metformin Hydrochloride), held by Watson Labs Inc, was first approved by FDA on Dec 14, 2004, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 14, 2004 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Discontinued |
| Aug 11, 2026 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 6, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 6, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Aug 20, 2010 | Supplement 5Labeling | Approved | None posted |
| Dec 14, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters